[
  {
    "ts": null,
    "headline": "Enterprise Software Extinction Via AI Exaggerated, Their Stocks Becoming Incredibly Cheap",
    "summary": "Enterprise software is not facing extinction from generative AI. Click here to read more about how incumbents are adapting and leveraging AI themselves.",
    "url": "https://finnhub.io/api/news?id=217760af81208910456eeee7bb309320b03d47b333a1c95059c803547206eecf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755464270,
      "headline": "Enterprise Software Extinction Via AI Exaggerated, Their Stocks Becoming Incredibly Cheap",
      "id": 136404276,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166649836/image_2166649836.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Enterprise software is not facing extinction from generative AI. Click here to read more about how incumbents are adapting and leveraging AI themselves.",
      "url": "https://finnhub.io/api/news?id=217760af81208910456eeee7bb309320b03d47b333a1c95059c803547206eecf"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner International Equity ADR Q2 2025 Commentary",
    "summary": "Harding Loevnerâs Q2 2025 report reveals health careâs sharp underperformance amid policy shocks and tech disruption. Explore resilient picks and future upside.",
    "url": "https://finnhub.io/api/news?id=b138f66b3e73ec6d5394697078d47344579fc1efeb753ddd0dcf29fed3304c31",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755459000,
      "headline": "Harding Loevner International Equity ADR Q2 2025 Commentary",
      "id": 136403626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217790397/image_1217790397.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Harding Loevnerâs Q2 2025 report reveals health careâs sharp underperformance amid policy shocks and tech disruption. Explore resilient picks and future upside.\n",
      "url": "https://finnhub.io/api/news?id=b138f66b3e73ec6d5394697078d47344579fc1efeb753ddd0dcf29fed3304c31"
    }
  },
  {
    "ts": null,
    "headline": "1 Beaten-Down Stock That Could Soar by the End of the Year",
    "summary": "The drugmaker has a major catalyst on the way.",
    "url": "https://finnhub.io/api/news?id=b4c7d484a270ec170ce5a33f951f74f07f8346be228632ddb59bac03429aa067",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755435300,
      "headline": "1 Beaten-Down Stock That Could Soar by the End of the Year",
      "id": 136408271,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker has a major catalyst on the way.",
      "url": "https://finnhub.io/api/news?id=b4c7d484a270ec170ce5a33f951f74f07f8346be228632ddb59bac03429aa067"
    }
  },
  {
    "ts": null,
    "headline": "Insider Buys Additional US$1.1m In Eli Lilly Stock",
    "summary": "NYSE:LLY 1 Year Share Price vs Fair Value Explore Eli Lilly's Fair Values from the Community and select yours Those...",
    "url": "https://finnhub.io/api/news?id=04c02134fa709e04a5c05a93c2fcfd583c3e5971218a49b6551e1fca91325975",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755434142,
      "headline": "Insider Buys Additional US$1.1m In Eli Lilly Stock",
      "id": 136408272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NYSE:LLY 1 Year Share Price vs Fair Value Explore Eli Lilly's Fair Values from the Community and select yours Those...",
      "url": "https://finnhub.io/api/news?id=04c02134fa709e04a5c05a93c2fcfd583c3e5971218a49b6551e1fca91325975"
    }
  },
  {
    "ts": null,
    "headline": "This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors",
    "summary": "The drugmaker's recent dip could also be a buying opportunity.",
    "url": "https://finnhub.io/api/news?id=bf8b93783f1868cb753d157b8d7981e5ad1db18590641c5266744ba794ea0b40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755429300,
      "headline": "This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors",
      "id": 136408273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker's recent dip could also be a buying opportunity.",
      "url": "https://finnhub.io/api/news?id=bf8b93783f1868cb753d157b8d7981e5ad1db18590641c5266744ba794ea0b40"
    }
  },
  {
    "ts": null,
    "headline": "Beam Therapeutics: A Slow-Developing Story",
    "summary": "Beam Therapeutics' base editing tech shows promise in sickle cell & AATD.",
    "url": "https://finnhub.io/api/news?id=5669c6603a4581cb3a47182464b01980192c8fe0b301f23507140e511a6604c8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755427830,
      "headline": "Beam Therapeutics: A Slow-Developing Story",
      "id": 136399882,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Beam Therapeutics' base editing tech shows promise in sickle cell & AATD.",
      "url": "https://finnhub.io/api/news?id=5669c6603a4581cb3a47182464b01980192c8fe0b301f23507140e511a6604c8"
    }
  },
  {
    "ts": null,
    "headline": "3 Fantastic Growth Stocks to Buy in August",
    "summary": "Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.",
    "url": "https://finnhub.io/api/news?id=2c8085968eddd68bd5e842c60dde1d0bcd7e1c4f7faf8d0e8dff80a44646400e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755427320,
      "headline": "3 Fantastic Growth Stocks to Buy in August",
      "id": 136408274,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.",
      "url": "https://finnhub.io/api/news?id=2c8085968eddd68bd5e842c60dde1d0bcd7e1c4f7faf8d0e8dff80a44646400e"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Maintains ‘Overweight’ Rating on Eli Lilly and Company (LLY) With $1,100 PT",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included in our list of the 11 Best Rebound Stocks to Buy According to Hedge Funds. On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and Company (NYSE:LLY) with a $1,100 price target. This target boost follows the company’s Q2 results. While investor sentiment weakened over […]",
    "url": "https://finnhub.io/api/news?id=c99e94b402fa47965a6884ab68fc508886839973504f07cbeefb89dc7ab35b5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755411235,
      "headline": "JPMorgan Maintains ‘Overweight’ Rating on Eli Lilly and Company (LLY) With $1,100 PT",
      "id": 136408275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included in our list of the 11 Best Rebound Stocks to Buy According to Hedge Funds. On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and Company (NYSE:LLY) with a $1,100 price target. This target boost follows the company’s Q2 results. While investor sentiment weakened over […]",
      "url": "https://finnhub.io/api/news?id=c99e94b402fa47965a6884ab68fc508886839973504f07cbeefb89dc7ab35b5b"
    }
  },
  {
    "ts": null,
    "headline": "Structure Therapeutics: Key Milestones Dead Ahead",
    "summary": "Structure Therapeutics: Key Milestones Dead Ahead",
    "url": "https://finnhub.io/api/news?id=f7a842f4e65ce894452a113177df28e2b87ee1feeec5e8db7ffdceaf8c07b61e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755409093,
      "headline": "Structure Therapeutics: Key Milestones Dead Ahead",
      "id": 136387392,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f7a842f4e65ce894452a113177df28e2b87ee1feeec5e8db7ffdceaf8c07b61e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Releases Q2 2025 Results",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, the company released Q2 2025 results, with revenues increasing 38% to $15.56 billion, thanks to the volume growth from Zepbound and Mounjaro. Furthermore, Eli Lilly and Company (NYSE:LLY) raised the midpoint of its 2025 full-year revenue […]",
    "url": "https://finnhub.io/api/news?id=b746e31be4176bf0b53ce81d33e0c40414ed98a860a2c6350d14b9f021bd21c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755406465,
      "headline": "Eli Lilly and Company (LLY) Releases Q2 2025 Results",
      "id": 136408276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, the company released Q2 2025 results, with revenues increasing 38% to $15.56 billion, thanks to the volume growth from Zepbound and Mounjaro. Furthermore, Eli Lilly and Company (NYSE:LLY) raised the midpoint of its 2025 full-year revenue […]",
      "url": "https://finnhub.io/api/news?id=b746e31be4176bf0b53ce81d33e0c40414ed98a860a2c6350d14b9f021bd21c6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Don't Bet Against This Biotech Powerhouse",
    "summary": "Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback is a buy-the-dip opportunity.",
    "url": "https://finnhub.io/api/news?id=d9ff3e0f94011882fa901828f2b17ce1e7a3b051fabd1a2b81d5507c3fc1a2d1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755394207,
      "headline": "Eli Lilly: Don't Bet Against This Biotech Powerhouse",
      "id": 136383707,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318526353/image_1318526353.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback is a buy-the-dip opportunity.",
      "url": "https://finnhub.io/api/news?id=d9ff3e0f94011882fa901828f2b17ce1e7a3b051fabd1a2b81d5507c3fc1a2d1"
    }
  }
]